- Read the article. The test for this nursing continuing professional development (NCPD) activity is to be taken online at www.nursingcenter.com/CE/CNS. Tests can no longer be mailed or faxed.
- You'll need to create an account (it's free!) and log in to access My Planner before taking online tests. Your planner will keep track of all your Lippincott Professional Development online NCPD activities for you.
- There's only one correct answer for each question. A passing score for this test is 7 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
- For questions, contact Lippincott Professional Development: 1-800-787-8985.
- Registration deadline is March 7, 2025
Lippincott Professional Development will award 2.0 contact hours and 1.0 pharmacology contact hours for this nursing continuing professional development activity.
Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.0 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida, CE Broker #50-1223. Your certificate is valid in all states.
Payment: The registration fee for this test is $21.95.
The drugs presented in this article have not received FDA approval for use in the US.
CE TEST QUESTIONS
LEARNING OUTCOME: Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the management of a patient with thyroid eye disease by achieving a minimum score of 70% on the outcomes-based posttest.
LEARNING OBJECTIVES: After completing this continuing professional development activity, the participant will be able to apply knowledge gained to a case scenario to:
1. Select common characteristics related to thyroid eye disease (TED).
2. Apply treatment strategies for a patient with TED.
- Which of the following individuals is in the group that is primarily affected by Graves’ disease?
- a 35-year-old woman
- a 67-year-old man
- a 72-year-old woman
- The active phase of thyroid-associated orbitopathy typically lasts up to a total of
- 6 months.
- 12 months.
- 24 months.
- Common signs and symptoms of TED include
- increased intraocular pressure.
- What oral supplement is suggested for treating patients with mild TED?
- Teprotumumab is a human monoclonal antibody
- CTLA-4 inhibitor.
- PD-1 inhibitor.
- IGF-IR inhibitor.
Case-based assessment: Placing yourself in the role of the nurse, use the scenario below to apply the knowledge and skills you learned in the attached article.
Questions #6 through #10 are based on this case scenario:
LS is a 44-year-old woman with a history of Graves’ disease and type 2 diabetes mellitus that is controlled with oral agents. She has a smoking history of 28 pack-years and is still an active smoker. One week ago, she presented to the office with a complaint of proptosis, diplopia, fatigue, and pain when she moves her eyes. After a visit to her ophthalmologist, she returns today to discuss potential treatments for TED.
- An important strategy that LS should pursue to control disease activity and decrease her risk of blindness is
- smoking cessation.
- increasing her activity level.
- weight loss.
- Because LS’ diabetes is controlled, she is a candidate for glucocorticoid therapy. If she agrees to this treatment, you will encourage her to receive intravenous therapy rather than oral therapy because intravenous therapy has resulted in
- fewer serious side effects.
- a shorter duration of therapy needed.
- fewer patients requiring eye surgery.
- LS tells you that she has seen television commercials advertising teprotumumab as a treatment for TED. When she asks you what adverse events she might get from the drug, what is included on your list?
- Although adverse events from teprotumumab are generally mild to moderate and resolve spontaneously during or soon after treatment is completed, additional adverse events to alert LS to include
- unilateral facial droop.
- hair loss.
- night sweats.
- Prior to beginning treatment with teprotumumab as well as during treatment and for 6 months after the last dose, it is important that LS
- uses effective contraception.
- checks her temperature daily.
- takes radioactive iodine tablets.